Recent Updates
Recently added Catalysts

Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.1Buniverse median $1.20B
Allocated capital$265M$1.1B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank245/299crowding rank 248

Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery is uncontested. Pacira Biosciences (PCRX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with ZILRETTA in phase 3.

There is no public comparable to price it against. PCRX spreads its $1.1B market cap across 4 indications, so $265M of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$265M of allocated capital sits in Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery, ranking it 245th of 299 indications by the money committed to it.

Companies developing drugs for Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
PCRXPacira BiosciencesZILRETTAPhase 31$1.1BNo4 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery has one competitor and a median of $1.1B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Idiopathic Membranous Nephropathy1 company · $279M · median $838MUncontestedPrevention of Acute Rejection in Renal Transplant1 company · $226M · median $226MUncontestedCOPD1 company · $167M · median $333MUncontestedPemphigus1 company · $148M · median $590MUncontestedAcute Respiratory Distress Syndrome1 company · $136M · median $272MUncontestedImmune Thrombocytopenic Purpura2 companies · $458M · median $1.1BOrphan cornerChronic Graft-versus-Host Disease1 company · $458M · median $1.8BUncontestedComplement 3 Glomerulopathy1 company · $461M · median $1.4BUncontested

Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery pipeline questions

Which biotech companies are developing drugs for Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery?

Pacira Biosciences (PCRX, ZILRETTA, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery.

How advanced is the Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery pipeline?

Of the 1 clinical-stage programme in Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery?

No. PCRX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery, which is why the indication is classified as uncontested.

When is the next Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery catalyst?

The next dated catalyst in Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery is PCRX on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map